Denovo Biopharma

Wen Luo, Ph.D. - Chief Executive Officer/Chief Scientific Officer

Dr. Wen Luo has 20 years of experience in biomedical research and industry including more than 10 years of experience in applying genomic technology in drug discovery and development. Prior to joining denovo biopharma, Dr. Luo managed the genomic group and provided bioinformatic supports to a broad range of research projects across a number of therapeutic areas including oncology, hematology, inflammation and metabolic diseases at Ligand Pharmaceuticals. He was also responsible for developing clinical biomarkers for drugs in various stages of clinical trials. Before joining Ligand, he was senior bioinformatician at Incyte Genomic, where he managed one of the largest proteomic databases at the time, LifePro. He was also involved in discovering novel human genes and splice variants, and he was the co-inventor of patents covering 100s of novel genes derived from these findings. Prior to Incyte Genomics, he was a research scientist at Sugen (acquired by Pharmacia and then by Pfizer) working on drug target identification and validation for a number of novel kinases discovered at Sugen. Dr. Luo was a Howard Hughes Medical Institute post-doc fellow at UCSF, and received his Ph.D. in molecular biology and biochemistry from Indiana University School of Medicine. Dr. Luo received Pre-Med training at Peking University and medical training at Peking Union Medical College .

Xiangming Fang, M.D., Ph.D. - Chief Operating Officer

Dr. Fang has 26 years of experience in biomedical research and product development, including 18 years of biotech industry experience and 14 years of management experience. She has strong scientific background with integrated knowledge in medicine, molecular and cell biology, immunology, genomics and proteomics. She was also involved in several startup companies with hands on experience in team building and operation. Previously as the Senior Vice President and Chief Scientific Officer at GenWay Biotech, she is responsible for new technology and product development and production, as well as customer support and partnership coordination. Prior to GenWay, Dr. Fang served at GenStar Therapeutics, initially as the Director of the Cancer Program and the Director of Preclinical Studies, then as Vice President, Hemophilia and Vector Development. Dr. Fang's earlier experiences include gene therapy product development for hemophilia at Baxter Healthcare and GeneMedicine Inc. Dr. Fang obtained her Medical Degree from Zhejiang University Medical School and Ph.D. in Molecular Biology from the University of Alabama . She completed her postdoctoral studies at the University of Texas , MD Anderson Cancer Center. Dr. Fang was the President (2009-2010) of Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA), San Diego chapter, and current Vice Chair of BOD.

Robert Little - Chief Business Officer

Robert Little has over 30 years commercial experience in the Pharmaceutical, Biotechnology and Device industries ,with many successes in Country Management, Global product Launches, and Business Development and Licensing. From 2006-2010, Mr. Little was VP and chief commericial officer at Halozyme, where he implemented a high performing commercial operations function at Halozyme including Business Development, Marketing, New Product Planning and Alliance Management, and helped to drove market cap from $100M to over $600M in four years. From 2003 -2006, Mr. Little was SVP at Neurocrine Biosciences, where he implemented a 200 strong commercial organization (Sales, Marketing, and New Product Planning) to initially co-promote Zoloft™ with Pfizer then eventually launch Indiplon for sleep disorders. Piror to 2003, Mr. Little was group vice president of global prescription business at Pharmacia after spending nearly 20 years at Pharmacia and Pharmacia & Upjohn. Mr. Little has had business experience working in 4 different countries, including many years working here in the US , and has deep experience in many therapeutic areas, particularly in Oncology, Endocrinology, Neuroscience, and Opthalmology. His additional successes include creating a global reimbursement and health outcomes function for a major Drug Company, as well as building ground up commercial organizations for three fledgling biotech companies. He has led successful licensing activities and over a 10 year period he created Licensing Agreements with an aggregate value of over 1 Billion dollars ( up front payments and milestones, excluding royalties).